- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®
mogamulizumab is an approved drug (PMDA (Japan, 2012), EMA & FDA (2018))
Compound class: Antibody
Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
1. Antoniu SA. (2010)
Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.
Curr Opin Mol Ther, 12 (6): 770-9. [PMID:21154168]
2. Honda T, Hishizawa M, Kataoka TR, Ohmori K, Takaori-Kondo A, Miyachi Y, Kabashima K. (2015)
Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.
Acta Derm Venereol, 95 (5): 606-7. [PMID:25424342]
3. Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, Morita A, Akinaga S, Ueda R. (2013)
Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma.
Cancer Sci, 104 (5): 647-50. [PMID:23360455]
4. Shitara K, Nakamura K, Hosaka E, Tanaka A, Koike M. (2009)
Monoclonal antibodies which preferentially bind to chemokine receptors, used for immunotherapy, as antiinflammatory, aniticarcinogenic agents and for prophylaxis of respiratory system disorders or antiallergens.
Patent number: US7504104. Assignee: Kyowa Hakko Kogyo Co., Ltd. Priority date: 31/08/2001. Publication date: 17/01/2010.